IO Biotech, Inc. (NASDAQ:IOBT – Get Free Report) saw a large growth in short interest in February. As of February 28th, there was short interest totalling 32,300 shares, a growth of 32.9% from the February 13th total of 24,300 shares. Based on an average daily volume of 181,100 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are sold short.
Institutional Investors Weigh In On IO Biotech
Large investors have recently bought and sold shares of the business. Citadel Advisors LLC bought a new stake in shares of IO Biotech during the fourth quarter worth $249,000. Dauntless Investment Group LLC bought a new position in shares of IO Biotech during the fourth quarter worth $688,000. XTX Topco Ltd bought a new position in IO Biotech during the fourth quarter worth about $26,000. Renaissance Technologies LLC grew its position in shares of IO Biotech by 22.5% in the 4th quarter. Renaissance Technologies LLC now owns 118,800 shares of the company’s stock valued at $109,000 after purchasing an additional 21,800 shares during the period. Finally, Landscape Capital Management L.L.C. acquired a new position in shares of IO Biotech in the fourth quarter valued at approximately $407,000. 54.76% of the stock is currently owned by institutional investors.
IO Biotech Stock Up 2.4 %
NASDAQ:IOBT traded up $0.02 on Monday, reaching $0.90. The stock had a trading volume of 27,901 shares, compared to its average volume of 259,705. The company has a market capitalization of $59.29 million, a P/E ratio of -0.66 and a beta of 0.22. IO Biotech has a 1-year low of $0.66 and a 1-year high of $1.85. The stock has a fifty day moving average price of $0.92 and a 200-day moving average price of $0.97.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on IO Biotech
About IO Biotech
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
Recommended Stories
- Five stocks we like better than IO Biotech
- How Can Investors Benefit From After-Hours Trading
- Can TikTok Stock Picks Really Make You Rich?
- The How And Why of Investing in Oil Stocks
- The “Quality” Rotation: Back to Basics Investing
- Learn Technical Analysis Skills to Master the Stock Market
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter.